UK Pharmaceutical Pricing Analysis: Impasse in ...

By Staff Writer

August 25, 2025

The accelerated review of the UK's Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) concluded without agreement in August 2025. The review focused on soaring payment rates. These require companies to pay up to 35.6% of the...
Eli Lilly’s Innovation Statement: Advocating Drug Pricing Reforms
Strengthening the U.S. Pharmaceutical Supply Chain: Establishing a Strategic ...
Urgent Care Effectiveness: Exploring Canadian Centre Models and Health System...
Achieving International Drug Price Parity: Trump’s Mandate
Navigating Challenges for Small Countries to Access Innovative Medicines
Mental Health Policy Integration: A Cross-Sector Imperative for Well-being an...
Urgent Call to Action for EU Clinical Trials Strategy
National Bulk Purchasing Strategy: Enhancing Drug Affordability and Access in...
Silencing Science Impact: Political Interference and Global Health Consequences
10-Year Health Plan: Transforming England’s NHS for the Future
EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030
Pharma Ad Spending Trends: Insights from the Top 10 Drug Advertisers of 2024